💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments:…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, steadily growing business, fully valued.
Cipla is scored on the pharma / healthcare framework. It keeps a healthy 13.3% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 1.02×). Free cash flow is worth about 1.4% of its market value.
Over the last 3 years revenue compounded at 8%/yr and profit at 11%/yr. Book value has grown 13%/yr. Return on equity is a modest 8.2%. In the latest quarter profit grew 43% versus the prior quarter.
At 29× earnings, the stock sits at the 61st percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price already implies ~18%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 39.88 | — | — |
| P/B | 3.22 | 4.1 | better |
| EV/EBITDA | 21.42 | 19.33 | worse |
| ROE | 8.18 | — | — |
| ROCE | 10.8 | 14.41 | worse |
| ROA | 6.6 | 1.64 | better |
| Quick Ratio | 2.5 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 8% CAGR — growing but slowly.
Profit is on a 2-year growth streak. Profit is growing faster than revenue (11% vs 8%) — margin expansion is at work.
Operating margins have been stable around 18% — no major structural shift.
ROE at 11% — modest; the capital isn't working hard.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. 11% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 10% sequentially — momentum is building.
Profit jumped 43% QoQ — check if this is operating leverage or a one-off item. Quarterly margins are compressing (17% → 11%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold just 29.2% — widely held; sentiment-driven. FIIs trimmed 3.7pp — foreign money is rotating out.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.